Nearly 90 percent survival for patients who received REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received REGN-EB3 Read More »

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced with Eli Lilly and Company ("Lilly") that the innovative PD-1 inhibitor Tyvyt® (sintilimab injection), co-developed by both companies, is the only PD-1 inhibitor that has been included in the new Catalogue of National Reimbursement Drug List ("NRDL") according to the latest announcement from the National Healthcare Security Administration ("NHSA"). Read More »

In an effort to advocate for the communities and members they serve, Inland Empire Health Plan (IEHP) CEO, Jarrod McNaughton, contributed to the California Pharmacy Carve Out discussion in the MJH Life Sciences publication, Managed Healthcare Executive to explain how it impacts IEHP members, providers and local community. Read More »

254 Walgreens will be added to Buckeye's Network Read More »

Expert, local dispensing and same-day delivery to be provided by experienced hospice pharmacy Read More »

Sentry Data Systems, Inc., a leader in pharmacy procurement and utilization management, 340B compliance and advanced healthcare analytics solutions, today announced the addition of Claims Manager Plus, an innovative new solution that helps hospitals adhere to payer reporting requirements — minimizing payer denials and accelerating payment for 340B covered entities' Medicaid pharmacy claims. Read More »

Three new CVS Pharmacy stores to open in the Portland area by end of 2019, bringing a health-centric retail pharmacy experience to the market Read More »

CHC Health has announced a strategic partnership with Catalyst Healthcare, an award-winning technology company, and Pack4U for delivery of connected care at home, to provide virtual pharmacist services for improving medication adherence and patient health outcomes. Read More »

Adding Drug Collection Units in 29 CVS Pharmacy Locations Across the State Read More »

Bryn's Epinephrine Nasal Spray has Two Doses in One Portable Device Read More »

Ademi & O'Reilly, LLP is investigating Achillion (NASDAQ:ACHN) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Achillion to Alexion. Read More »

Acquisition bolsters Eyevance's position as an emerging leader in treating anterior segment and ocular surface conditions Read More »

Florida-based SMP Pharmacy Solutions announces strategic acquisition of Northridge Plaza Pharmacy to serve growing demand in California fertility market Read More »

A Trifecta of Relief Formulated with HydroCell™ Technology Offers New Artificial Tear Options for Patients Suffering from Eye Dryness Read More »

MedicaSafe will combine the generic version of Suboxone® (buprenorphine and naloxone) with its smart medication systems to treat opioid dependence Read More »

PANTHERx is excited to announce that it is the first pharmacy nationwide that has been awarded the Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). Read More »

Acquisition is expected to realize over $10M in annual synergies Read More »

TWILIGHT Study Fails to Answer Key Scientific Question Regarding Most Efficacious Treatment Post-PCI Read More »

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), for the potential treatment of Stage IIb-IV melanoma. Read More »

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma, Rare Disease & Gene Therapy, being held September 23-24, 2019 in New York City. Read More »